A

    Aurinia Pharmaceuticals Inc (AUPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.29
    -0.18 (-1.12%)

    Market Cap: $2.17B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    +16.82%
    Streak
    10 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.22
    Range$0.21 - $0.25
    5 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate Drift
    90d ago$0.24+10.2%
    60d ago$0.24+10.2%
    30d ago$0.24+10.2%
    7d ago$0.24+8.2%
    Current$0.22
    Revenue Consensus
    $83M
    Range$80M - $87M
    7 analysts
    Dec 31, 2026
    EPS Consensus$0.29
    Range$0.24 - $0.35
    5 analysts
    Revenue Consensus
    $88M
    Range$82M - $96M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.29---
    Sep 26EST
    		-$0.22---
    Jun 26
    		$0.28$0.18+55.56%Beat+75.0%
    Mar 26
    		$0.25$0.16+56.25%Beat+56.3%
    Dec 25
    		$0.26$0.21+23.81%Beat+2500.0%
    Sep 25
    		$0.23$0.16+43.75%Beat+130.0%
    Jun 25
    		$0.16$0.15+6.67%Beat+1500.0%
    Mar 25
    		$0.16$0.10+60.00%Beat+328.6%
    Dec 24
    		$0.01$-0.02+162.50%Beat+105.3%
    Sep 24
    		$0.10$0.02+400.00%Beat+211.1%
    Jun 24
    		$0.01$0.01+0.00%Beat+112.5%
    Mar 24
    		$-0.07$-0.14+50.00%Beat+61.1%
    Dec 23
    		$-0.19$-0.16-18.75%Miss-5.6%
    Sep 23
    		$-0.09$-0.17+47.06%Beat-50.0%
    Jun 23
    		$-0.08N/A+57.89%Beat+68.0%
    Mar 23
    		$-0.18$-0.22+18.18%Beat+33.3%
    Dec 22
    		$-0.18$-0.27+33.33%Beat+28.0%
    Sep 22
    		$-0.06N/A+68.42%Beat+84.6%
    Jun 22
    		$-0.25$-0.22-13.64%Miss+32.4%
    Mar 22
    		$-0.27$-0.27+0.00%Beat+32.5%
    Dec 21
    		$-0.25$-0.27+7.41%Beat-400.0%
    Sep 21
    		$-0.39$-0.33-18.18%Miss-30.0%
    Jun 21
    		$-0.37$-0.36-2.78%Miss-42.3%
    Mar 21
    		$-0.40$-0.38-5.26%Miss-73.9%
    Dec 20
    		$-0.05N/A+79.17%Beat+93.6%
    Sep 20
    		$-0.30$-0.24-25.00%Miss-42.9%
    Jun 20
    		$-0.26$-0.24-8.33%Miss-52.9%
    Mar 20
    		$-0.23$-0.34+32.35%Beat-43.8%
    Dec 19
    		$-0.78$-0.21-271.43%Miss-358.8%
    Sep 19
    		$-0.21$-0.18-16.67%Miss+0.0%
    Jun 19
    		$-0.17$-0.17+0.00%Beat-6.3%
    Mar 19
    		$-0.16$-0.18+11.11%Beat-6.7%
    Dec 18
    		$-0.17$-0.18+5.56%Beat-325.0%
    Sep 18
    		$-0.21$-0.19-10.53%Miss-31.2%
    Jun 18
    		$-0.16$-0.17+5.88%Beat-33.3%
    Mar 18
    		$-0.15$-0.17+11.76%Beat+25.0%
    Dec 17
    		$-0.04N/A+71.43%Beat+81.0%
    Sep 17
    		$-0.16$-0.12-33.33%Miss+23.8%
    Jun 17
    		$-0.12$-0.13+7.69%Beat-
    Mar 17
    		$-0.20$-0.12-66.67%Miss-
    Dec 16
    		$-0.21$-0.11-90.91%Miss-
    Sep 16
    		$-0.21$-0.13-61.54%Miss-

    Key Metrics

    Valuation
    P/E Ratio15.97EV/EBITDA9.86x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin100.80%Operating Margin55.70%
    ROE66.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage36.71x
    Current Ratio5.42xQuick Ratio4.97x
    Trading Statistics
    Beta1.40Avg Volume1.18M
    52-Week High$19.2552-Week Low$10.34

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.33
    SMA 20$15.84
    SMA 50$15.99
    SMA 200$15.47
    EMA 10$16.30
    EMA 20$16.05
    EMA 50$15.88
    EMA 200$14.89

    MACD

    Line: 0.26Signal: 0.16Hist: 0.10

    ADX

    ADX: 24.5+DI: 31.9-DI: 17.2

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down20.0
    PSAR$15.23

    Bollinger Bands

    Upper Band$17.29
    Lower Band$14.40
    %B Position1823%(Upper)
    Band Width0.65

    RSI (14-Day)

    Neutral
    54.0

    Momentum Oscillators

    Stoch %K52.9
    Stoch %D56.8
    Williams %R-52.1
    ROC (10d)5.3%
    Momentum0.82
    CCI (20d)53.7
    MFI (14d)46.6

    Volatility Measures

    ATR (14d)$0.55(3.4%)
    StdDev (20d)0.72
    Hist Vol46.2%(High)

    Volume Flow

    VWAP$16.34
    OBV62.0M
    AD Line30.8M
    CMF (20d)0.029

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.5x
    VWMA (20d)$15.92

    Pivot Points

    R3$16.99
    R2$16.82
    R1$16.65
    Pivot Point$16.48
    S1$16.31
    S2$16.14
    S3$15.97

    Advanced Oscillators

    TSI11.14
    Ultimate Osc52.9
    KST40.13

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$83.22M$77.70M$77.11M$73.47M$70.01M$62.47M$59.87M$67.77M$57.19M$50.30M$45.09M$54.52M
    Cost of Revenue$6.55M$6.50M$8.80M$8.18M$7.12M$8.57M$5.55M$6.04M$8.91M$7.75M$5.39M$6.77M
    Gross Profit$76.67M$71.20M$68.31M$65.29M$62.89M$53.89M$54.31M$61.74M$48.28M$42.55M$39.70M$47.75M
    Operating Expenses$30.32M$29.78M$35.08M$35.55M$42.81M$32.04M$55.98M$49.99M$49.80M$55.80M$69.37M$64.01M
    R&D$13.05M$7.47M$10.89M$8.44M$7.43M$5.74M$8.11M$3.05M$4.08M$5.55M$10.23M$13.61M
    SG&A$23.51M$22.03M$29.25M$26.18M$26.02M$20.34M$37.03M$42.37M$44.93M$47.70M$50.07M$47.76M
    Operating Income$46.34M$41.42M$33.24M$29.75M$20.08M$21.85M$-1,669,000$11.75M$-1,513,000$-13,253,000$-29,674,000$-16,263,000
    Interest Income$3.39M$3.52M$3.50M$3.32M$3.19M$3.57M$3.99M$4.27M$4.19M$4.53M$4.57M$4.51M
    Interest Expense$948,000$1.01M$1.05M$1.10M$1.12M$1.07M$1.15M$1.21M$1.20M$1.28M$1.31M$1.40M
    Income Before Tax$48.79M$43.92M$35.69M$31.96M$22.16M$24.35M$1.17M$14.81M$1.48M$-10,010,000$-26,416,000$-13,149,000
    Income Tax Expense$11.37M$9.57M$-175,104,000$411,000$643,000$1.00M$-256,000$457,000$756,000$739,000$459,000$298,000
    Net Income$37.41M$34.35M$210.79M$31.55M$21.51M$23.34M$1.43M$14.35M$722,000$-10,749,000$-26,875,000$-13,447,000
    EBITDA$49.29M$43.92M$35.77M$31.98M$22.38M$24.05M$214,000$13.22M$205,000$-11,612,000$-28,030,000$-14,238,000
    EBIT$46.34M$41.42M$33.24M$29.75M$20.08M$21.85M$-1,669,000$11.75M$-1,513,000$-13,253,000$-29,674,000$-16,263,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AUPH

    News

    Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

    Aurinia Pharmaceuticals' Chief Legal Officer, Stephen P. Robertson, sold 20,975 shares of company stock valued at $355,945 on August 26, according to an SEC filing. This insider transaction occurred as Aurinia Pharmaceuticals shares were down 1.55%, trading at $16.74. The company, focused on autoimmune diseases, reported strong revenue growth, high gross margins, positive EPS, and prudent debt management, though its Price to Sales ratio indicates potential overvaluation.

    Benzinga•8/26/26•
    Somewhat-Bearish

    Aurinia (NASDAQ: AUPH) legal chief sells shares to cover taxes

    Aurinia Pharmaceuticals Inc.'s Chief Legal Officer, Stephen P. Robertson, sold 20,975 shares of common stock at a weighted average price of $16.97 per share on August 21, 2026. This transaction was primarily conducted to cover tax withholding obligations associated with the vesting of Performance Stock Units. Following this sale, and including 360 shares acquired through an employee share purchase plan, Robertson beneficially holds 600,787 common shares.

    Stock Titan•8/26/26•
    Somewhat-Bearish

    Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes

    Aurinia Pharmaceuticals Inc. (AUPH) officer Stephen P. Robertson plans to sell up to 47,000 common shares on or after August 21, 2026, through Morgan Stanley Smith Barney LLC. This sale is intended to cover tax withholding obligations associated with the vesting of performance stock units. The proposed sale has a neutral impact and sentiment according to Rhea-AI.

    Stock Titan•8/22/26•
    Neutral

    Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

    Aurinia Pharmaceuticals (AUPH) reported strong Q1 2026 earnings, beating the Zacks Consensus Estimate with $0.25 per share against an expected $0.18. The company also surpassed revenue expectations, bringing in $77.71 million compared to the estimated $77.41 million. Despite these positive results, Aurinia's stock performance year-to-date has lagged the S&P 500, and it currently holds a Zacks Rank #3 (Hold).

    Eastern Progress•8/21/26•
    Bullish

    Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement

    Aurinia Pharmaceuticals has reached a patent settlement with Teva Pharmaceutical Industries, preventing Teva from launching a generic version of Lupkynis in the U.S. until December 7, 2036. This agreement removes a significant generic threat, strengthening Aurinia's intellectual property protection and driving an after-hours stock increase of up to 6%. The company still faces litigation from other generic challengers but is advancing its pipeline with new studies and drug candidates.

    BigGo Finance•8/20/26•
    Neutral

    Frequently Asked Questions About AUPH

    Does AUPH pay dividends?
    Aurinia Pharmaceuticals Inc (AUPH) does not currently pay a regular dividend.
    What is AUPH's P/E ratio?
    Aurinia Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 15.97.
    What is AUPH's market cap?
    Aurinia Pharmaceuticals Inc (AUPH) has a market capitalization of $2.17B with a current stock price of $16.29.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In